课题基金 / 基金详情

Non-genomic resistance mechanisms in EGFR-mutant lung cancer

Non-genomic resistance mechanisms in EGFR-mutant lung cancer
EGFR突变肺癌的非基因组耐药机制
批准号:
10442329
负责人:
Aaron N Hata
金额:
$40.85万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
未结题
起止时间:
2009-03-01 至 2027-05-31

项目摘要

项目成果

Aaron N Hata的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结
英文摘要
Project Summary Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is the current standard of care for first-line therapy for EGFR mutant lung cancer patients. While osimertinib is effective in inducing tumor regressions, improving quality of life and prolonging survival in most patients, it is not curative. Early studies of acquired resistance suggest that even after standard histologic and genomic assessments for resistance mechanisms, a substantial portion of osimertinib resistance remains uncharacterized. This incomplete understanding of osimertinib resistance poses a significant barrier to developing new and effective therapies for clinical use. We hypothesize that, in contrast to earlier generation EGFR inhibitors, non-genomic mechanisms are driving the majority of acquired resistance to first-line osimertinib. To date, assessments of EGFR TKI acquired resistance mechanisms have focused on genomic resistance mutations, amplifications, and fusions, in part because these can be readily detected in tumor tissue or in blood-based ctDNA liquid biopsies. In this project we seek to discover the spectrum of non-genomic osimertinib resistance. Our main objective is to identify both tumor intrinsic mechanisms of osimertinib resistance as well as tumor extrinsic microenvironmental resistance mechanisms. In Aim 1, we will use RARE-Seq, a novel blood-based assay to quantify tumor gene expressions patterns of resistance in EGFR mutant NSCLC patients relapsing on osimertinib. In Aim 2, we will investigate tumor cell extrinsic mechanisms of osimertinib resistance by leveraging our robust translational infrastructure to develop cancer-associated fibroblast models from osimertinib resistance biopsies. We will use these models to dissect functional interactions between CAFs, tumor cells and immune cells, and we will integrate these results with spatial molecular analysis of clinical biopsies. Collectively, the studies described in this proposal will generate a comprehensive picture of osimertinib resistance and set the stage for future development of therapies that overcome resistance to osimertinib.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms driving lung cancer evolution during targeted kinase inhibitor treatment
  • 批准号:
    10377999
  • 项目类别:
  • 资助金额:
    $52.8万
  • 财政年份:
    2020
  • 负责人:
    Aaron N Hata
  • 依托单位:
Mechanisms driving lung cancer evolution during targeted kinase inhibitor treatment
  • 批准号:
    10591501
  • 项目类别:
  • 资助金额:
    $48.39万
  • 财政年份:
    2020
  • 负责人:
    Aaron N Hata
  • 依托单位:
High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizers
  • 批准号:
    10433852
  • 项目类别:
  • 资助金额:
    $55.47万
  • 财政年份:
    2018
  • 负责人:
    Aaron N Hata
  • 依托单位:
High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizers
  • 批准号:
    10194409
  • 项目类别:
  • 资助金额:
    $75.35万
  • 财政年份:
    2018
  • 负责人:
    Aaron N Hata
  • 依托单位:
海外基金